What Does the Delta Variant Mean for Inovio Pharmaceuticals' Stock?
The race to be the first to make a coronavirus vaccine is over, but that doesn't mean the competition has ended. Inovio Pharmaceuticals (NASDAQ: INO) wasn't exactly a contender for the top spot during the vaccine-development scramble in 2020. Its candidate, INO-4800, will only start its phase 3 clinical trials sometime this summer.
But now, the rise of the delta variant might be threatening the effectiveness of its flagship project, which was designed to combat the original version of the virus. If Inovio's jab doesn't cut the mustard, it might not even get approved. On the other hand, there's reason to believe that success against the delta variant won't guarantee a higher stock price. Let's investigate a bit further to see why that might be the case.
Image source: Getty Images.
Source Fool.com
